Status:

WITHDRAWN

BAFF Levels and Lupus Nephritis (LN)

Lead Sponsor:

Universidad de Antioquia

Collaborating Sponsors:

ARTMEDICA

Conditions:

Lupus Nephritis

Eligibility:

FEMALE

18+ years

Brief Summary

B-cell activating factor (BAFF), serves as a vital survival and differentiation factor for normal B-cell development. BAFF levels have been associated with the clinical activity of SLE in humans. BAFF...

Detailed Description

1.3. Research question Flares of lupus nephritis are related to the behavior of BAFF levels before, during, and after induction therapy. 2\. Theoretical framework B-cell activating factor (BAFF), als...

Eligibility Criteria

Inclusion

  • Patients are older than 18 years
  • Patients that fulfill any of the available classification criteria for systemic lupus erythematosus
  • Patients with new-onset lupus nephritis or with lupus nephritis relapse after successful remission.
  • Patients with a diagnosis of lupus nephritis according to Wallace and Dubois criteria
  • Patients with class III and IV lupus nephritis with or without Class V lupus nephritis.

Exclusion

  • Women with a positive pregnancy test
  • Class I, II, V lupus nephritis without Class III or IV lupus nephritis
  • Patients with an active malignancy or active treatment for malignancy.
  • Patients with kidney disease with GFR \<30ml / min
  • Patients with severe leukopenia
  • Patients with active infection

Key Trial Info

Start Date :

January 1 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 1 2023

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04369495

Start Date

January 1 2021

End Date

January 1 2023

Last Update

May 13 2024

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.